Sanofi ADR looks cheaper on two of the three valuation measures in this snapshot. BeiGene has the lower PEG and higher return on equity, so the comparison isn’t one-sided.
Sanofi ADR (SNY) and BeiGene, Ltd. (ONC) are both in Health Care, within Pharmaceuticals, Biotechnology & Life Sciences. At the October 30, 2026 adjusted close, SNY was US$44.34, with a market cap of US$106.2B. ONC was US$370.33, with a market cap of US$42.1B. Share prices alone don’t show which company is cheaper. The valuation multiples offer a more useful, though incomplete, comparison.
Investor takeaway: Sanofi has the lower P/E and P/B, while BeiGene has the lower PEG. Sanofi comes out ahead on two of the three available multiples. That doesn’t prove SNY is undervalued, ONC is overvalued, or either stock will outperform. The measures reflect different aspects of valuation and should be considered alongside each company’s performance and risks.
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
Sanofi ADR
SNY.US
Health Care
$45.33
$109.14B
1D
-0.48%
1W
+8.21%
BeOne Medicines AG
ONC.US
Health Care
$355.00
$40.39B
1D
-1.74%
1W
-3.02%
Sanofi is cheaper on two of three supplied multiples
SNY has the lower P/E (22.1 versus 66.2) and P/B (1.30 versus 8.09). ONC has the lower PEG (0.78 versus 31.46). Sanofi looks cheaper on more of these measures, but the split shows why no single multiple can settle the question of value.
Bull case
Sanofi’s lower P/E of 22.1 and P/B of 1.30 may appeal to investors comparing these multiples. Its analyst consensus is Buy, with a target price of US$53.61.
Bear case
Sanofi’s PEG is 31.46, well above BeiGene’s 0.78. Its trailing return on equity is also lower: 5.7% versus 14.7% for BeiGene. These figures add context to Sanofi’s lower P/E and P/B, but this snapshot doesn’t explain the differences.
The valuation table mostly favours Sanofi
Sanofi has the lower P/E and P/B: 22.1 versus 66.2 for P/E, and 1.30 versus 8.09 for P/B. The PEG comparison favours BeiGene, at 0.78 versus Sanofi’s 31.46. Sanofi therefore looks cheaper on two of the three multiples, but these measures don’t establish either company’s intrinsic value or capture every difference between them.
| Measure | Sanofi ADR (SNY) | BeiGene (ONC) |
|---|---|---|
| P/E | 22.1 | 66.2 |
| PEG | 31.46 | 0.78 |
| P/B | 1.30 | 8.09 |
| ROE TTM | 5.7% | 14.7% |
Returns, analyst ratings and company size add context
BeiGene’s trailing return on equity is 14.7%, compared with 5.7% for Sanofi. That difference may matter when weighing Sanofi’s lower P/E and P/B against BeiGene’s lower PEG. The snapshot doesn’t explain what’s driving the figures or how they may change. Both stocks have a dividend yield of 0.00%.
The analyst consensus ratings are Buy for Sanofi and Strong Buy for BeiGene. Their target prices are US$53.61 and US$436.46, respectively. These are estimates from this snapshot, not guarantees of future prices. Sanofi’s market cap is US$106.2B, compared with BeiGene’s US$42.1B. For company details, see Sanofi ADR and BeiGene.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
